老年癫痫患者新型抗癫痫药物的治疗进展  

Progress of new anti-seizure medications in elderly patients with epilepsy

作　　者：齐婧 刘霄 王群[1] Qi Jing;Liu Xiao;Wang Qun(Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,China National Clinical Research Center for Neurological Diseases,Beijing 100070,China)

机构地区：[1]首都医科大学附属北京天坛医院神经病学中心国家神经系统疾病临床医学研究中心,北京100070

出　　处：《中华神经科杂志》2022年第10期1185-1190,共6页Chinese Journal of Neurology

基　　金：国家“十三五”慢性病重大专项(2017TFC1307500);首都卫生发展科研专项(首发2016-1-2011,首发2020-1-2013);北京自然科学基金重点项目(Z200024)。

摘　　要：随着人口迅速的老龄化,老年癫痫很可能成为最常见的癫痫形式之一。近年来,第三代抗癫痫药物拉考沙胺、吡仑帕奈、布瓦西坦、醋酸艾司利卡西平已被美国食品药品监督管理局和欧洲药品管理局批准用于癫痫发作的单一治疗和(或)辅助治疗。文中总结了老年癫痫患者使用第三代抗癫痫药物的疗效及耐受性,阐述了药物对认知及情绪的影响、药物间相互作用等,旨在为临床医生选择第三代抗癫痫药物提供可靠的依据。With the rapid aging of the population,elderly epilepsy probably becomes one of the most common forms of epilepsy.Lacosamide,brivaracetam,eslicarbazepine acetate,and perampanel have been approved by the United States Food and Drug Administration and the European Medicines Agency for monotherapy and(or)adjunctive treatment of seizures in the last few years.This review summarizes the efficacy and tolerability of third-generation anti-seizure medications in elderly epilepsy patients and introduces the effects of anti-seizure medications on cognitive function and mood,as well as drug-drug interactions,aiming to provide a reliable basis for clinicians to choose third-generation anti-seizure medications.

关 键 词：癫痫 老年人 药物疗法 药物耐受性 

分 类 号：R742.1[医药卫生—神经病学与精神病学]